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Abstract 
 
BACKGROUND: We know little about how well the goals and results of clinical trials in 
Parkinson disease (PD) reflect the priorities of patients and the broader PD community.  
 
OBJECTIVES: We conducted a review of registered trials on clincialtrials.gov between 
2007-2016 to explore whether PD trials have moved closer to the therapeutic priority 
goals articulated by the PD community.  
 
METHODS: Using the search terms “Parkinson”, “interventional trials”, phase “0-4”, we 
categorized therapeutic PD studies from clinicaltrials.gov between 1/1/2007-12/31/2016. 
766 trials met criteria for analysis. We explored temporal trends in the utilization of 
balance problems and falls, mood symptoms including stress and anxiety, cognitive 
dysfunction including dementia, and dyskinesias as primary outcomes. We analyzed 
trials where recruitment was listed as “completed” (n=391) to explore publication rates.  
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RESULTS: Balance problems and falls were listed as primary outcome measures in 125 
studies (16.3%), cognitive measures in 48 (6.3%), mood features in 37 (4.8%), and 
dyskinesias in 30 (3.9%). Trials using balance problems and falls as a primary outcome 
increased in frequency per year between 2007 and 2016 (Z=-2.128, p=0.033) unlike the 
proportion of trials evaluating cognitive dysfunction including dementia (Z=-0.380, 
p=0.704), mood symptoms including stress and anxiety (Z=0.345, p=0.730), or 
dyskinesias (Z=0.340, p=0.734) which did not show temporal changes. 231 (59.1%) 
completed trials had results published in manuscript form as of 5/1/2017, leaving 40.9% 
of trials unpublished.  
 
CONCLUSIONS: PD trials focusing on balance problems and falls are becoming more 
common. About 40% of completed PD trials are unpublished, reflecting suboptimal 
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The successful conduct of clinical trials in Parkinson disease (PD) relies on a 
covenant of shared priorities between investigators and the PD community.1 The design 
and execution of PD clinical trials is nearly always contingent upon the successful 
recruitment & retention—often with the added complexity of blinding and 
randomization—of interested participants prepared to not only donate their time and 
effort but also willing take on the prospect of intervention-associated risks,2 all done for 
the small prospect of hypothetical future benefits conferred to many people affected by 
PD, including hopefully themselves.3 This contribution by trial participants and their 
This article is protected by copyright. All rights reserved.
Wyant et al. 5 
caregivers is one that justifies their role as stakeholders in the development, design, 
and conduction of relevant clinical trials.4  
Many feel that engaging relevant clinical populations in priority-setting decisions 
about the relative merits of different trials is an important basic principle of ethical 
clinical research.5-7 Collaborative partnerships between disease-focused community 
groups and trial funders and investigators also yield a practical benefit— better 
recruitment, improved projected adherence, and higher rates of subject retention all are 
favorable signs for a trial’s chances of success.8, 9 Perhaps more importantly, 
collaborative partnerships between researchers and research subjects offer the 
potential to shift a research field’s objectives towards the priorities of patients and their 
caregivers, which may differ from those of researchers.10 Efforts by previous groups 
have worked towards this goal by trying to understand patient-and-community priorities 
for therapeutic development in variety of different disease states including PD, where 
top PD-community priority goals related to new treatment development were identified 
in 2014: treatments for “balance problems and falls”, “stress and anxiety”, “dyskinesias”, 
and “dementia”.4, 11  
 In a separate effort to improve both the access to clinical trials & trial results as 
well as improve the coordination of sponsors and the output delivered to the American 
public, the United States (US) Congress passed the Food and Drug Administration 
(FDA) Amendments Act (FDAAA) of 2007 that required all applicable clinical trials of 
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drugs or devices to be registered on the publically-accessible clinicaltrials.gov website 
beginning in 2007.12 The FDAAA also legally required study teams to update 
clincialtrials.gov with certain data related to a trial’s ongoing conduct including 
enrollment, adverse events, and results as they become available. These rules have 
been revisited by international clinical trial oversight bodies13 and the FDAAA itself was 
revised in 2016 to further clarify reporting rules.14 Despite variable reporting of data 
related to ongoing study conduct,15 clinicaltrials.gov serves as an indexed registry of all 
applicable PD therapeutic clinical trials since 2007.  
We conducted a review of registered PD clinical therapeutic trials on 
clinicaltrials.gov over a ten-year period between 2007 and 2016 to explore how well trial 
primary outcomes aligned with the goals of the PD community at large. Given that PD-
specific foundations have increasingly helped to empower and advocate for the broader 
PD community in the arena of clinical trials,16, 17 we hypothesized that PD clinical trial 





Using the search terms “Parkinson” and advanced filters “interventional studies”, 
phase “0-4”, and a date range of studies first posted between 1/1/2006 and 12/31/2016, 
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we identified a total of 1297 studies. Datasets were downloaded from clincialtrials.gov 
between 8/17/16 and 2/15/17. After study team review (Figure 1) 531 studies were 
excluded: 195 because they began either prior to 2007 or after 2016, 82 were not trials 
of therapeutic interventions, 175 did not include PD participants in their enrollment, and 
79 enrolled participants without synuclein-related disorders. The remaining 766 studies 
were registered trials of therapeutic interventions that limited enrollment to either only 
PD participants or to participants with PD and other synucleinopathies. 
We extracted data about the intended primary therapeutic outcome marker for 
eligible PD clinical trials from their postings on clincaltrials.gov. We specifically sought to 
categorize trials that employed markers of “balance problems and falls”, “cognitive 
features including “dementia”, “dyskinesias”, and mood features including “stress and 
anxiety” as primary outcome measures. These four outcome measures--along with a 
fifth clinical research priority focused on understanding disease heterogeneity in PD--
were selected on the basis of a PD patient and community survey conducted by Deane 
et al. as the final top 5 “prioritized and ranked uncertainties for the management of 
Parkinson disease”, with an overarching research aspiration being the goal of finding an 
effective cure for Parkinson disease.4 We conducted an exploratory analysis to 
determine whether trials focusing on motor fluctuations (including both dyskinesia 
treatment and/or increase-in “on-time”/reduction-in-“off time” as outcome markers) had 
changed in frequency over this time frame. We also tracked the use of the Unified 
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Parkinson’s Disease Rating Scale (UPDRS) or the Movement Disorders Society revised 
UPDRS (MDS-UPDRS) motor exam and total (parts 1-3) as a primary outcome 
reference group. For studies reporting multiple primary outcome markers, we restricted 
our categorization of primary outcomes to no more than 2 outcome measures per study. 
Study team members (K.W, V.K) reviewed outcome measures and trial characteristics 
to determine whether the primary objective of a given trial matched one of the four pre-
specified categories identified by Deane et al.  
 
Publication analysis in completed trials 
 
We conducted a literature search to explore publications related to clinical trials whose 
recruitment was complete (n=391) in May of 2017. We searched Pubmed, Google 
Scholar, Medline, and ISI Web of science. We used an initial search term of the trial 
NCT number registered on clinicaltrials.gov. When no publications were found, we then 
used additional search terms in an advanced search using linkage term “and” including 
last name and first initial of the principal investigator, “Parkinson*”, and a key word(s) 
from the title of the trial registered on clinicaltrials.gov. We coded studies as either 
published or not published based on these factors. Abstracts and abstract summaries 
drawn from meetings were coded as not published since they generally lacked salient 
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details on study design, primary outcome measures, efficacy of randomization, and 
study conduct. 
Funding sources for published relevant clinical trials were determined through a 
review of a study’s posting on clinicaltrials.gov. Organizations listed as either the 
“Sponsor” or, when relevant, as “Collaborator” were identified as study funders. Eligible 
funding agencies were categorized as one of five categories: Industry organizations, 
United States (US) Federal organizations, US Medical Centers/Universities/Research 





Descriptive statistics, including means, proportions, and percentages, were used 
to categorize eligible PD trials over the 10-year period. The Cochran-Armitage test of 
trend was used to explore temporal changes in the use of balance problems and falls, 
dyskinesias, cognitive symptoms including dementia, and mood symptoms including 
stress and anxiety as primary outcomes. Clinical trials were categorized according to 
the year they began. We hypothesized that PD trials would show an increasing trend 
towards utilization of these primary outcomes over time. In the subset of trials whose 
recruitment was listed as “completed” on clincialtrials.gov, we used chi-square testing to 
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explore whether funding source category associated with peer-reviewed publication 
status of trial results. This retrospective study was granted not regulated status by the 





766 PD therapeutic trials were registered between 2007 and 2016 (Table 1). 
Balance problems and falls as a primary outcome measure were listed in 125 studies 
(16.3%), cognitive measures including dementia in 48 (6.3%), dyskinesias in 30 (3.9%) 
and mood features including stress and anxiety in 37 (4.8%). Trials using balance 
problems and falls as a primary outcome measure increased in frequency/year over the 
study period (Cochran-Armitage test of trend Z=-2.128, p=0.033) (Figure 2). To 
determine whether this increase was due to an increasing trend of physiotherapy or 
exercise trials focused on gait and balance, we categorized interventions among the 
125 balance studies as ones involving any element of physiotherapy/exercise (n=60) vs. 
all others (n=65). No significant trend was seen for an increasing frequency of 
physiotherapy/exercise trials over the 2007-2016 timeframe (Z=-0.935, p=0.351). Trials 
employing cognitive measures including dementia (Z=-0.380, p=0.704), dyskinesias 
(Z=0.340, p=0.734), or mood features including stress and anxiety (Z=0.345, p=0.730) 
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as primary outcomes did not show any change in proportion-per-year over the 10-year 
study period. There were no changes in the proportion of trials focusing on motor 
fluctuations, including either dyskinesias and/or optimization of on/off-time as a primary 
outcome marker, but rather a non-significant trend towards a decrease in the proportion 
of these trials (Z=1.854, p=0.064) over this 10-year period. Trials using either part III 
(motor exam summative score) or total score of either the UPDRS or MDS-UPDRS as a 
primary outcome were listed in 75 (9.8%) and 38 (5.0%) studies respectively. Neither 
UPDRS/MDS-UPDRS motor exam nor total scores showed a relative increase in use 
over this 10-year period [motor exam: (Z=0.873, p=0.383); total exam: (Z=0.038, 
p=0.969)] 
Of the 766 total trials, 554 (72.3%) involved some element of randomization. 
Trials involving US Federal funding were more likely to be randomized (χ2=5.31, 
p=0.021). 375 trials (49.0%) were double blinded. Industry sponsored trials were more 
likely to be double-blinded (χ2=38.33, p<0.0001) and trials funded by individual US 
Medical Centers/Universities/Research Institutes were less likely to be double blinded 
(χ2=5.51, p =0.019). A total of 350 (45.7%) of trials were placebo controlled. Trials 
receiving Industry funding (χ2=28.94, p<0.0001) or a medical foundation funding 
(χ2=4.31, p=0.038) were more likely to use a placebo.  
Of the 391 studies with completed recruitment, 231 (59.1%) had results 
published in manuscript form, leaving 40.9% of trials with complete recruitment as 
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unpublished (Figure 3). Among studies that began in the first half of our study window 
(between 2007 and 2011 (n=234)), 29.5% were unpublished. Of studies with complete 
recruitment that began between 2012 and 2016 (n=157), 57.96% were unpublished. 
Among the 391 completed-recruitment studies, receiving funding from a medical 
foundation (n=29) associated with a higher likelihood of a trial being published (χ2=4.80, 
p=0.029). The Michael J. Fox Foundation (n=20) and the National Parkinson 
Foundation (n=4) were the two most common foundation funding agencies. There were 
no significant associations between publication status and receiving funding from an 
Industry source (n=184, χ2=0.007, p=0.933), individual US Medical 
Centers/Universities/Research Institutes (n=61, χ2=0.301, p=0.583), or US Federal 
organizations (n=22, χ2= 1.334, p=0.248). Of the 766 registered PD therapeutic trials, 
338 (44.1%) had performance sites in the US. Of the 391 completed trials, studies with 
performance sites in the US (n=176 of 391; 45%) showed a similar rate of publication 




Parkinson disease clinical trials are increasingly focusing on treatments of 
balance problems and falls as primary outcomes, a trend favored by individuals with PD 
and PD researchers as well.4, 18 This is a good sign. Our findings, however, do not 
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suggest any increase in the proportion of trials focusing on other key PD community 
research goals such as cognitive impairment including dementia, mood features 
including stress and anxiety symptoms, or dyskinesias. Only about 60% of all registered 
PD trials with complete recruitment between 2007 and 2016 have published their results 
in manuscript form. This is a concerning finding. Completed trials funded by extramural 
medical foundations were more likely to be published in contrast to studies funded by 
Industry, US federal agencies, or US single-center medical centers. Collectively, these 
findings are both a sign of optimism and point to future directions for targeted 
improvement in PD clinical trials planning and execution. 
 Balance problems and falls are significant determinants of disability in PD and 
strong risk factors for subsequent cognitive decline and mortality.19, 20 PD balance 
impairments commonly have multifactorial etiologies, varied early clinical 
manifestations, and no well-validated set of outcome parameters with which to track 
either disability or the efficacy of therapeutic interventions, making the design and 
conduct of clinical trials more challenging.21-23 Parkinson’s researchers in a panel 
commissioned by the US National Institute of Neurological Disorders and Stroke 
(NINDS) recognized the goal of developing treatments for gait and balance impairments 
as one of their top 2 ranked clinical research priorities along with understanding 
prodromal disease progression.18 A limitation of clincaltrials.gov is that trials of 
interventions other than drugs or devices—i.e. those that are not FDA regulated—such 
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as exercise or physical therapy may not always be registered and subsequently may not 
be captured. For example, a recent review of PD fall-prevention clinical trials with >100 
participants since 2011 revealed 2 drug trials and 5 exercise-related trials.23 Trends 
towards increasing emphasis on gait and balance markers in PD trials are encouraging 
and suggest an increasing alignment between patient and researcher priorities in PD 
therapeutic development. 
 Registered clinical trials focusing on cognitive impairment including dementia, 
mood symptoms including stress and anxiety, and dyskinesia burden as primary 
outcomes remain a relatively small fraction of the body of PD trials and are not 
becoming more common. The growth of non-pharmacological cognitive training 
interventions, with variable registration on clinicaltrials.gov, may be one reason why the 
percentage of drug or device interventions remain static.24, 25 The lack of change in the 
dyskinesia trial proportion may reflect increasing utilization of deep brain stimulation for 
management of PD motor fluctuations including dyskinesias.26 Alternatively, the ability 
to successfully recruit for anti-dyskinesia trials may be challenging given their 
temporally-limited prevalence among people with PD.27, 28 Mood disorders in PD include 
depression, apathy, and anxiety. Each are commonly seen as early features in the 
natural history of PD.29 It is possible that non-motor mood symptoms remain under-
recognized by patients and providers, contributing to an under-prioritization of their 
treatment as a primary objective of trials.30 It is also possible that patients with 
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symptoms of anxiety or depression are, by virtue of the severity of their affective 
disease burden, more reluctant to participate in clinical trials in general, limiting the 
enthusiasm for such primary outcome targets on the part of funding agencies. It should 
be noted that the Deane et al. study enrolled a cohort of PD community members in the 
United Kingdom (UK). It is possible that their ranked priorities may not mirror those of 
PD community members in other countries including the US. 
 Approximately 40% of completed PD clinical trials were not published in 
manuscript form in peer-reviewed journals. This is a high number that points to 
inefficiencies and wasted participant effort in the PD trials enterprise. Similar concerning 
trends have been seen in other neurological disorders as well.31 We found it was not 
uncommon for large completed trials to be presented in abstract form at national or 
international meetings, only to be shrouded from public view afterwards--searchable in 
some cases through an aggregate list of hundreds of published abstracts using only a 
subset of scientific literature search engines. Given the lack of details about study 
design, planned primary outcomes, blinding, randomization, and recruitment targets, 
these abstracts are not able to sufficiently inform a reader about whether a 
hypothesized treatment intervention was successful or not. It is important to also note 
that published data for recently completed trials may be forthcoming and in general and 
should be viewed differently from trials that completed enrollment many years ago. 
Interestingly, trials receiving funding from PD foundations were more likely to be 
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published than those receiving funding from other sources. This is an encouraging 
finding that suggests US medical foundations such as the Michael J Fox Foundation 
among others may currently be identifying successful elements of trial execution in the 
peer-review stage. Our data are of limited granularity but overall, they give us no reason 
to believe that non-foundation trials are more poorly designed than foundation-
sponsored trials. One of several possible reasons foundation-sponsored trials may be 
more likely to be published include a tighter and more transparent bond between 
stakeholders who fund a given foundation and their expectation of a return on 
investment. This may lead to a more explicit directive for foundations and their staff to 
be involved in the public dissemination of foundation-funded trials. One would imagine 
that this is less true in US federally funded studies. The US National Institutes of Health 
recognized this issue related to non-publication of trial findings32 and in 2017 revised its 
policies to better “exercise proper stewardship of precious public resources”.33 Industry 
sponsored trials, though they are characterized by rigorous scientific planning and well-
coordinated execution, may be initiated for reasons that differ from non-Industry trials. 
Understanding the factors for non-publication of clinical trials is an issue with emerging 
public health relevance. 
 Our presented analyses have several limitations. First, they rely on accurate 
reporting of trial parameters by the study team through the clinicaltrials.gov website. It is 
possible that inaccurate trial registration details may have led us to over- or under-
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estimate the true prevalence of certain primary outcomes. Given the heterogeneity of 
reporting quality seen in more complex elements of study registration data—such as 
blinding, phase of trial, secondary outcome measures, etc.—we did not utilize these 
more advanced data to answer other impactful questions about changes in PD trial 
design over the 2007-2016 time period. Registration in clincialtrials.gov is legally 
mandated for US FDA-regulated studies and is typically encouraged, though not 
required, for other clinical trials aiming to publish results in US-affiliated journals. By 
relying only on clincialtrials.gov, we did not capture a broad cohort of studies from other 
websites in use across Asia, Europe, South America, Africa, and other regions of the 
world where PD is common and where trial registration requirements differ. It is also 
possible that some of the 2007-2016 longitudinal temporal trends seen in our study do 
not reflect the true distribution of all PD therapeutic clinical trials, but instead more 
closely reflect an increasing familiarity among study teams with the use of the 
clincialtrials.gov website. We also note that we excluded studies that recruited 
participants without synucleinopathies (e.g. recruitment cohorts that included both 
Parkinson disease and Alzheimer’s disease subjects). These exclusion criteria allowed 
us to more specifically assess PD-focused trials but may also have impacted our 
findings.  
 A PD clinical trial is often the end result of years of preclinical and translational 
research. Developing systematic ways to give PD patients and community members a 
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greater say in research goals and priorities is likely to yield a body of trials that more 
efficiently use finite human resources and whose end results better suit the needs of 
intended consumers. Clear first steps towards this goal might include reaching out to 
PD community members to serve on scientific review panels, a practice already being 
conducted by a number of PD funding agencies. Others have favored using a measure 
of “relevance” as pre-funding review criteria.10 Equally important may be giving PD 
community members an identified forum—perhaps via social media or through 
Parkinson-related meetings—to influence the ideas of PD scientists. Either way, a more 
common vision of shared priorities between researchers and PD community members is 
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Figure 1: Flow chart of Parkinson disease clinical trials from clincialtrials.gov 
Figure 2: Trends in four categories of primary outcomes in registered Parkinson 
disease clinical trials (2007-2016)  
Figure 3: Peer-reviewed published manuscripts among completed Parkinson disease 
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Table 1: Primary Outcomes in applicable Parkinson disease clinical trials 2007-2016 












Primary Outcomes N (%) N (%) 
Gait/Balance 125 (16.3%) 50 (12.8%) 
Cognitive 48 (6.3%) 24 (6.1%) 
Mood 37 (4.8%) 16 (4.1%) 







88 (11.5%) 75 (19.2%) 
UPDRS/MDS-UPDRS 
Motor exam 
75 (9.8%) 38 (9.7%) 
Biomarker Primary 
Outcomes 
62 (8.1%) 26 (6.6%) 
Optimizing On/Off-time 61 (8.0%) 39 (10.0%) 
UPDRS/MDS-UPDRS 
Total exam 
38 (5.0%) 19 (4.9%) 
UPDRS: Unified Parkinson’s Disease Rating Scale; MDS-UPDRS: Movement Disorders 
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